Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Combo Vaccine for Influenza and COVID-19 Looks Promising in Early Study

Robust Immune Responses Elicited by Combination Vaccine

A new development in the field of immunization has emerged with the successful early study of a combination vaccine for influenza and COVID-19. This innovative approach, spearheaded by Pfizer-BioNTech, could alter the future landscape on how healthcare professionals tackle these two respiratory diseases.

Key Points

  • The combination vaccine candidate elicited robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
  • Positive topline results were announced from a phase 1/2 study evaluating the immunogenicity, safety, and tolerability of Pfizer-BioNTech’s mRNA-based combination vaccine candidate.
  • The study included approximately 990 healthy adults aged 18 to 64 years.
  • The safety profile of the vaccine candidate was consistent with that observed for Pfizer-BioNTech’s COVID-19 vaccine.
  • A phase 3 trial evaluating the mRNA-based combination vaccine is expected to begin in the coming months.
  • The vaccine candidate has received Fast Track designation from the Food and Drug Administration.

“This vaccine has the potential to lessen the impact of two respiratory diseases with a single injection and may simplify immunization practices for providers, patients, and health care systems all over the world.”
— Annaliesa Anderson, PhD, FAAM, Senior Vice President and Head, Vaccine Research and Development at Pfizer

More on Vaccines/Immunization

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form